Home › Research › Treatments
Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study
Sandipan Bhattacharjee, Asad E Patanwala, Wei-Hsuan Lo-Ciganic, Daniel C Malone, Jeannie K Lee, Shannon M Knapp, Terri Warholak, William J Burke. Alzheimer's & dementia (New York, N. Y.), 2019-07-10
Topic: Drug trials: efficacy and safety
In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as-treated analysis. Difference in hazards of all-cause hospitalization among index AD medication groups was observed in ITT analysis but not in as-treated analysis. Significant differences exist in terms of mortality and hospitalization risk with different AD medication initiation in real-world setting.
Key findings
- In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as-treated analysis.
- Difference in hazards of all-cause hospitalization among index AD medication groups was observed in ITT analysis but not in as-treated analysis.
- Significant differences exist in terms of mortality and hospitalization risk with different AD medication initiation in real-world setting.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants21,558
- Evidence strengthModerate
How this study scored 71/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 40 of the 56 points we could judge it on, which is 71 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 4 / 4 | 21,558 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31338414) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 40 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 40 of the 56 points we could judge it on is 71 out of 100. |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Bhattacharjee, S., Patanwala, A. E., Lo-Ciganic, W.-H., Malone, D. C., Lee, J. K., Knapp, S. M., et al. (2019). Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1016/j.trci.2019.05.005
Vancouver
Bhattacharjee S, Patanwala AE, Lo-Ciganic W.-H, Malone DC, Lee JK, Knapp SM, et al. Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. Alzheimer's & dementia (New York, N. Y.). 2019. doi:10.1016/j.trci.2019.05.005. PMID: 31338414.
BibTeX
@article{bhattacharjee2019-31338414,
author = {Bhattacharjee, Sandipan and Patanwala, Asad E and Lo-Ciganic, Wei-Hsuan and Malone, Daniel C and Lee, Jeannie K and Knapp, Shannon M and Warholak, Terri and Burke, William J},
title = {{Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2019},
doi = {10.1016/j.trci.2019.05.005},
pmid = {31338414},
url = {https://doi.org/10.1016/j.trci.2019.05.005}
}